Categories: News

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2022 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., July 25, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, August 10, 2022, at 3:00 p.m. Eastern Time, Shockwave Medical management is scheduled for a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference, which is taking place from Monday, August 8 – Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA.

Interested parties may access live and archived webcasts of these events on the “News & Events” section of the company’s investor website at https://ir.shockwavemedical.com.  

To access the live second quarter 2022 earnings call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com 

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com 

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

8 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

8 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

1 hour ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago